StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Beam Therapeutics's total debt was $100.26M at Jun 30, 2026.

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$100.26M–
Q1 FY2026Mar 31, 2026$100.19M–

More Beam Therapeutics figures

See a number that looks wrong?